UBS Analysts See Genmab Moving From Turnaround Toward Takeoff
UBS analysts say three positive late-stage clinical trials signal a shift for the Danish biotech company.
UBS analysts say three positive late-stage clinical trials signal a shift for the Danish biotech company.